What MagIA Diagnostics does

MagIA diagnostics SAS is a French in-vitro diagnostics (IVD) company founded in 2017 and headquartered in Échirolles (Grenoble). The company develops a portable point-of-care immunoassay platform built on proprietary superparamagnetic nanoparticle chemistry combined with structured micro-magnet architecture, originating from doctoral research at G2Elab and Institut Néel. Its flagship MforScreen reader weighs under 3.5 kg, runs for over 10 hours on battery, and accepts one or two single-use cartridges simultaneously. The paired MagIA Test Kit (H3S) performs multiplexed screening for HIV, Hepatitis B, Hepatitis C, and Syphilis in 12-15 minutes from 50 µl of capillary or venous blood. A laboratory-format variant, MforLab, extends the same chemistry to a 96-well plate format for bioproduction monitoring under the MAGI@Line project.

The business is currently pre-commercial: products are not yet CE marked, with submission targeted for 2025 following Phase 3 MAGICIENS clinical validation on approximately 6,700 samples. Revenue mechanics are anchored on future hardware (reader) sales paired with consumable cartridge revenue, complemented by European grant funding and collaborative research project income (MAGFA, MAGESTICS, Grand Défi Bioproduction). The go-to-market is a B2B enterprise field-sales motion targeting French and European hospitals, mobile screening units, sub-Saharan African public health programs (via Institut Pasteur and African NGO partners), and biopharmaceutical manufacturers for bioprocess analytics. Go-to-market is reinforced by presence at MEDICA, SFLS, EuroTestWeek, and the Lyonbiopôle/Novéka! cluster. The company has 23 employees, ISO 13485:2016 certification (September 2023), and cumulative funding of approximately €8.2 million across grants, seed, crowdfunding, and a 2024 IVD strategic round, with an additional €5 million earmarked via the European MAGFA project.

Name

MagIA Diagnostics

Legal name

MagIA diagnostics SAS

Website

https://magia-diagnostics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

MagIA Diagnostics designs portable point-of-care immunoassay readers and multiplexed cartridges that screen for HIV, Hepatitis B/C, and Syphilis from a finger-prick blood sample in 12-15 minutes, serving hospitals, mobile screening units, public health programs in sub-Saharan Africa, and bioproduction customers.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Point-of-care diagnostics
• Infectious disease screening
• Multiplex immunoassay
• Bioproduction monitoring
• Rapid diagnostic tests

Headquarters

HQ city

Échirolles

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D

Revenue model

1. Point-of-Care Diagnostic Kits and Readers: Sale of portable diagnostic devices (readers) and associated test cartridges for infectious disease screening. Revenue generated from hardware sales combined with consumable test kits.
2. Laboratory Diagnostic Solutions: MforLAB platform for bioproduction monitoring and laboratory-scale analysis, including 96-well format devices and monitoring services.
3. European Research Project Funding: MAGFA project with €5 million European funding; MAGESTICS project partnership with Infynity Biomarkers SAS and CHU Grenoble Alpes; Grand Défi Bioproduction funding for technology adaptation.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

MagIA Diagnostics designs, develops, and manufactures a portable point-of-care immunodiagnostic platform based on superparamagnetic nanoparticles and structured micro-magnets. The MforScreen reader paired with proprietary MagIA Test cartridges performs multiplexed screening for HIV, Hepatitis B, Hepatitis C, and Syphilis from a single 50 µl blood sample in 12-15 minutes. The company also offers MforLab, a 96-well laboratory format for bio-production monitoring and mini-bioreactor control.

Product overview

MagIA Diagnostics offers a unified platform approach centered on two product lines: MforScreen (point-of-care) and MforLab (laboratory). The core MforScreen system is a portable immunodiagnostic reader paired with proprietary MagIA Test Kits (H3S) that perform multiplexed rapid screening for HIV, Hepatitis B, Hepatitis C, and Syphilis from a single blood sample. The MforLab variant adapts the same technology for bioproduction monitoring in 96-well format. The company is expanding through two strategic projects: MAGFA (focused on Sub-Saharan Africa screening) and MAGESTICS (expanding to bacterial STIs).

Differentiator

Problem solved

Functional benefit

Brands

• MforScreen: Point-of-Care portable diagnostic reader system weighing less than 3.5 kg with over 10 hours autonomy, supporting 1 or 2 cartridges simultaneously
• MagIA test
• MAGICS H3S
• MAGFA
• MAGESTICS

Products and services

• MforScreen Point-of-Care Reader Portable point-of-care diagnostic reader device weighing under 3.5 kg with over 10 hours of battery autonomy. Supports 1 or 2 cartridges simultaneously and records test results for traceability. Used by hospitals, clinical labs, and mobile screening teams for decentralized infectious disease testing.
• MagIA Test Kit (H3S Multiplex Cartridge) Multiplexed rapid screening cartridge performing up to 5 analyses per cartridge (including 1 internal control) and up to 10 analyses per patient. Delivers results in 12-15 minutes using 50 µl of capillary blood, serum, plasma, or venous blood. Currently configured for combined HIV, Hepatitis B, Hepatitis C, and Syphilis detection.
• MforLab 96-Well Laboratory Format Laboratory-format version of the MagIA platform in 96-well format, designed for bio-production monitoring and real-time control of cell culture processes, including automated tracking of up to 24 mini bioreactors. Targeted at biopharmaceutical manufacturers, CMOs, and academic bioprocess laboratories.

Quantifiable outcome

• 6,700 samples tested for clinical validation
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, key and minor.

• Institut PasteurcoreStrategic or Co-development Partner · 1 October 2024European MAGFA project coordination with Institut Pasteur for combined screening of HIV, hepatitis B/C, and syphilis in sub-Saharan Africa. Institut Pasteur serves as data analysis subcontractor for clinical studies.
• GARDIENS DE VIEScoreStrategic or Co-development PartnerNGO partnership for MAGFA project field coordination in the Democratic Republic of Congo. Dr. Olivier Kana leads national operations with site visits to Kinshasa for project planning.
• Lyonbiopôle Auvergne-Rhône-AlpescoreGTM or Marketing PartnerRegional healthcare cluster supporting MEDICA exhibition delegation and European project accompaniment for MagIA diagnostics.
• TWB (Toulouse White Biotechnology)coreStrategic or Co-development PartnerMAGI@Line project for 96-well format installation and bioproduction monitoring. TWB serves as industrial integrator for demonstrating real-time cell culture monitoring.
• INFYNITY BIOMARKERS SASkeyStrategic or Co-development PartnerMAGESTICS project partnership to expand IST testing to include bacterial infections (Syphilis, Chlamydia, Gonorrhea) alongside viral infections.
• CHU Grenoble AlpescoreStrategic or Co-development PartnerClinical collaboration for MAGESTICS project and preliminary validation studies for hepatitis B diagnostic demonstrator.
• French Healthcare AssociationminorGTM or Marketing PartnerMembership to leverage international promotion network for healthcare French companies.
• TIBHkeyStrategic or Co-development PartnerInstallation of 96-well format immunochemistry device for MAGI@Line project demonstration.
• LRGP (Laboratoire Réactions et Génie des Procédés)minorStrategic or Co-development PartnerAcademic partner for Grand Défi Bioproduction project on biomedicament measurement technology.
• CIC/CHUGAkeyStrategic or Co-development PartnerClinical investigation center collaboration for preliminary validation of hepatitis B IVD demonstrator with real patient analysis.
• LinksiumminorGTM or Marketing PartnerGrenoble-based startup accelerator providing support and mentorship for deeptech challenges.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• bioMérieux: Global French IVD leader with extensive portfolio in clinical microbiology and immunoassays, including POC solutions. Directly comparable as a French-headquartered infectious disease diagnostics company with overlapping customer base (hospitals, reference labs) and competing POC platforms.
• Abbott Diagnostics: Global leader in rapid diagnostic tests including Determine HIV/Hepatitis and Binax platforms used widely in African screening programs and European hospitals. Competes with MagIA across both its POC infectious disease core business and bioproduction QC opportunities.

Direct peers

• Cepheid (Danaher): Pioneer of molecular POC diagnostics (GeneXpert), widely deployed for HIV, hepatitis, and STI screening in resource-limited settings including sub-Saharan Africa. Closely comparable as a multiplexed infectious disease POC platform competing for the same African public health and hospital tenders that MagIA targets.
• QuidelOrtho: Specialized POC diagnostics company with strong portfolio in rapid infectious disease testing (Sofia, Triage). Directly comparable as a multiplexed rapid immunoassay player targeting similar hospital and outreach screening customers as MagIA.
• Biosynex: French-headquartered POC diagnostics company specializing in rapid infectious disease tests (COVID, HIV, hepatitis). Direct comparable as a France-based POC competitor with overlapping target markets in Europe and Africa.
• NG Biotech: French POC diagnostics company developing rapid multiplexed immunoassays for infectious disease and women's health. Direct comparable based on shared geography (France), technology category (multiplexed rapid immunoassays), and target applications (infectious disease POC).
• OraSure Technologies: US POC diagnostics company focused on infectious disease screening (HIV, HCV) with significant presence in public health programs. Comparable as a multiplexed rapid screening platform targeting similar at-risk and outreach screening use cases.
• Mologic (Abbott Rapid Diagnostics): UK-based rapid diagnostics developer with strong focus on tropical and infectious disease POC tests, now part of Abbott. Comparable as a small-to-mid-stage POC innovator targeting global health and resource-limited settings.

Emerging players

• Atomo Diagnostics: Australian POC diagnostic company developing integrated rapid test devices for HIV and infectious diseases. Comparable as an emerging player in the rapid multiplexed POC space with similar early-stage commercial dynamics.
• MedMira: Canadian rapid diagnostics company with multiplexed POC tests for HIV, hepatitis, and syphilis. Comparable as a smaller, growth-stage POC infectious disease diagnostics peer with overlapping menu of tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@magiadiagnostics9753
• Facebookfacebook.com/MagiaDiagnostics
• LinkedInlinkedin.com/company/magia-diagnostics/mycompany

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MagIA Diagnostics